Sildenafil Citrate Tablet, Film Coated
Product Images NDC 68071-3646

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 68071-3646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3646 1)

Sildenafil 50 mg tablets packaging label from NuCare Pharmaceuticals, Inc. The label includes the product name Sildenafil 50 mg, quantity of 10 tablets, and specifies each film-coated tablet contains Sildenafil Citrate equivalent to 50 mg Sildenafil. It describes the tablet as oval-shaped, beveled edge, biconvex, green, debossed with 50 on the obverse and SC on the reverse. The label also features storage instructions, a warning to keep out of reach of children, and various regulatory barcodes and codes.*

FDA Label Image

Sildenafil_fig1.jpg (Sildenafil Fig1)

A line graph showing the mean change from baseline in sitting systolic blood pressure over 24 hours comparing Sildenafil 100 mg to placebo in healthy volunteers. The x-axis represents time post dose in hours and the y-axis shows systolic blood pressure change in mmHg.*

FDA Label Image

Sildenafil_fig3 (Sildenafil Fig 3)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing blood pressure change over an 8-hour period. Two lines represent data for Doxazosin plus placebo and Doxazosin plus Sildenafil 50 mg, depicting change in systolic blood pressure (mmHg) on the y-axis and time postdose (hours) on the x-axis.*

FDA Label Image

Sildenafil_fig_4 (Sildenafil Fig 4)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' that depicts changes in systolic blood pressure (mmHg) over 8 hours after dosing. It compares two groups: Doxazosin + Sildenafil 100 mg and Doxazosin + Placebo. The y-axis shows blood pressure changes from -50 to 40 mmHg, while the x-axis represents time in hours from 0 to 8.*

FDA Label Image

Sidenafil_fig_5 (Sildenafil Fig 5)

A line graph showing mean plasma concentrations of Sildenafil over 24 hours in healthy male volunteers after a commercial tablet dose. The Y-axis represents plasma concentration (ng/ml) and the X-axis shows time post-dose (hours). Concentration peaks shortly after dosing and declines steadily to near zero by 24 hours.*

FDA Label Image

Sildenafil-fig7 (Sildenafil Fig7)

A bar chart showing the percentage of patients reporting improvement across different treatments: Placebo (24%), Sildenafil Tablets 25 mg (63%), Sildenafil Tablets 50 mg (74%), and Sildenafil Tablets 100 mg (82%). The vertical axis represents the percentage of patients, and the horizontal axis lists the treatment groups with sample sizes.*

FDA Label Image

Str (Sildenafil Structure)

Chemical structure of Sildenafil, the active ingredient in Sildenafil Citrate 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc.*

FDA Label Image

Figure2 (Sildenafil Fig2)

A line graph comparing the change in blood pressure (DBP in mmHg) over time (hours postdose) between treatments with Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The graph shows two trend lines depicting blood pressure changes over an 8-hour period postdose.*

FDA Label Image

Sildenafil_fig6b (Sildenafil Fig6b)

A bar chart showing the percentage of patients at endpoint across different baseline scores (0 to 5). Multiple colored bars represent various groups or conditions for each baseline score category. The y-axis measures the percentage of patients, and the x-axis marks the baseline score values.*

FDA Label Image

Sildenafil_fig6a (Sildenafil Figure6a)

A bar chart depicting the percentage of patients at endpoint versus baseline score. The x-axis shows baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint ranging from 0% to 80%. Multiple bars per baseline score indicate different patient groups or conditions as distinguished by the legend on the right, which includes several categories represented by various fill patterns and shading.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.